NCT06030076View on ClinicalTrials.gov

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Plaque Psoriasis
Interventions
DRUG

Tildrakizumab

As provided in real-world clinical practice.

Trial Locations (1)

8010

RECRUITING

Gesundheitszentrum Citypark Graz, Graz

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY

NCT06030076 - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter